# Canada Finalises PMPRB Drug Pricing Rules: Key Takeaways

> Canada’s June 2025 PMPRB Guidelines changed how staff identify patented medicines for potential excessive-price review.

Canonical: https://goldentriangleconsultants.com/news-and-insights/f/canada-finalises-pmprb-drug-pricing-rules-key-takeaways/

Date: 2 July 2025

Canada’s PMPRB published its updated Guidelines in June 2025, marking a significant shift in how staff identify patented medicines for potential excessive-price review.

When Canada began modernising the Patented Medicine Prices Review Board (PMPRB) framework in 2017, few expected the process to run for most of the following decade. The updated Guidelines published on 30 June 2025 finally provided the industry with a clearer view of the next phase.

The new Guidelines take effect from January 2026 and are important because they change the role of the guidance itself. Rather than functioning as a framework that effectively establishes routine price ceilings for manufacturers to follow, the Guidelines are primarily designed to explain how PMPRB staff will identify cases that may warrant deeper review and potentially a hearing.

## A two-step review process

The framework introduces a more explicit screening process. Staff first review patented medicines using available domestic and international price information. Products raising concerns can then move into a more detailed review, where additional statutory factors and context can be considered.

This places greater emphasis on case selection and procedural transparency. Crucially, the Guidelines do not themselves make a legal finding that a medicine’s price is excessive. That determination remains a matter for the Board through the statutory hearing process.

## International comparisons remain important

International price comparisons continue to matter, so Canada remains highly relevant in global launch and IRP planning. Manufacturers should still understand how Canadian pricing sits against comparator countries and how changes in international prices could alter the risk profile of a product over time.

The practical difference is that the new framework is less naturally interpreted as a single formulaic “compliant price”. This increases the importance of understanding the facts of each product rather than relying solely on a threshold calculation.

## What pricing teams should do

Companies launching patented medicines in Canada should revisit their scenario models ahead of the January 2026 implementation date. Models should include Canadian list-price options, comparator-country evolution, therapeutic-class benchmarks and the potential effect of launch sequencing.

Teams should also maintain a clear evidence trail for the rationale behind pricing decisions. A transparent internal record becomes more valuable in a regime where products can progress from routine monitoring into deeper review based on a combination of pricing signals and case-specific factors.

## Global implications

Canada remains both a major pharmaceutical market and an important reference country. The final Guidelines therefore matter beyond Canadian compliance. They add another layer of uncertainty to international price optimisation and reinforce the need to model price corridors dynamically rather than treating each country as an isolated launch decision.

*This article reflects the market and policy context at the date of publication.*

## Further reading

- [PMPRB Guidelines for Staff](https://www.canada.ca/en/patented-medicine-prices-review/services/legislation/guidelines.html)
## Need to model the global pricing impact?

Golden Triangle Consultants develops bespoke pricing, market access and IRP tools to help teams test launch, price and revenue scenarios.